Logan Coy Related postsAn Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin with Pembrolizumab vs Pembrolizumab Monotherapy as First-Line Treatment in PD-L1 High Advanced NSCLC (BE6A LUNG-02)September 11, 2026A Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)September 11, 2026A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)September 11, 2026 Previous postA Phase 1, Open-Label, Multicenter Study of the Pharmacokinetics and Safety of Pralatrexate in Advanced Solid Tumor or Hematological Malignancy with Normal or Mild/Moderate/Severe Hepatic ImpairmentNext postA Phase 1b/2 Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Newly Diagnosed Acute Myeloid Leukemia (AML)